Alex White (Dublin South, Labour)
Link to this: Individually | In context

Question 684: To ask the Minister for Health in view of the proven efficacy of Pradaxa in preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, and its potential to alleviate over-extended warfarin phlebotomy services, if he will clarify the policy position of the Health Service Executive in funding the prescription of this drug under the general medical scheme; and if he will make a statement on the matter. [4038/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

Pradaxa is available on prescription to patients availing of the GMS and the Drug Payment Schemes for the prevention of venous thromboembolism in adult patients who have undergone elective hip replacement surgery or elective knee replacement surgery. The HSE is assessing the availability of resources in 2012 to consider long term treatment with Pradaxa for the prevention of stroke in patients with atrial fibrillation. This is a complicated process with long term implications.

The HSE has written to all GMS doctors and community pharmacy contractors to clarify the position in relation to Pradaxa. The HSE will continue to update healthcare professionals in relation to the matter. The HSE does not intend to disturb established therapeutic regimens for patients whose treatment with Pradaxa for the prevention of stroke was initiated prior to the recent clarification.